NCT04091022 2025-12-17
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
University of Alabama at Birmingham
Phase 2 Completed
Clinical Trials
18 trialsNCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02794428 2024-10-16
Chemoprevention of Gastric Carcinogenesis
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00204789 2019-12-16
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Phase 2 Completed
NCT00005884 2019-12-13
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
University of Wisconsin, Madison
Phase 3 Completed
NCT00983580 2019-09-04
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006079 2018-10-25
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT00006101 2018-05-14
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT00601640 2017-03-23
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
University of Arizona
Phase 2 Completed
NCT00118365 2015-01-22
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003814 2013-12-18
Eflornithine in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00086736 2013-11-19
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
University of Alabama at Birmingham
Phase 2 Completed
NCT00003076 2012-12-19
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Completed